EBM News
EBM News

COVID-19 vaccine development at early stage in India; breakthrough unlikely within a year: Experts

NEW DELHI: As Indian firms scramble to develop a vaccine for coronavirus, experts feel that research in the country is still at a nascent stage and any concrete breakthrough is not likely within a year. The Indian government and private firms have stepped up efforts to develop a vaccine to halt the spread of COVID-19 which has claimed over 3,700 lives with more than 1,25,000 cases in the country.

Referring to a vaccine to fight the virus, a PMO statement had said that it is the most pressing need and Indian academia, start-ups and industry have come together in cutting-edge vaccine design and development.

The Department of Biotechnology has been made a central coordination agency to identify pathways for vaccine development.

Naming the Indian firms working on vaccines for COVID-19, Gagandeep Kang, executive director of the Translational Health Science and Technology Institute, Faridabad, had said last month that while Zydus Cadila is working on two vaccines, Serum Institute, Biological E, Bharat Biotech, Indian Immunologicals, and Mynvax are developing one vaccine each.

The WHO has listed Serum Institute of India, Zydus Cadila, Indian Immunologicals Limited and Bharat Biotech from India among the firms involved in developing a vaccine.